Exciting Financial Outlook for TG Therapeutics Amid Growth
Upcoming Conference Call for Financial Results
TG Therapeutics, Inc. (NASDAQ: TGTX) has announced an upcoming conference call set for Monday at 8:30 AM ET. This call will focus on the financial results for the second quarter of 2025 and will provide insights into the company's business outlook for the rest of the year. The call will be hosted by Michael S. Weiss, the Chairman and Chief Executive Officer of TG Therapeutics.
How to Join the Conference Call
To participate in the conference call, callers can dial 1-877-407-8029 within the U.S., or 1-201-689-8029 for international access. The title of the conference is "TG Therapeutics Earnings Call." For those who prefer to join online, a live webcast will be accessible through the Events page in the Investors & Media section of the company's official website.
Audio Replay Available
An audio recording of the conference call will be made available for replay on the company's website for a duration of 30 days following the call. This ensures that stakeholders and interested parties can catch up on the important discussion points at their convenience, enhancing transparency and engagement.
Financial Disclosure Details
Prior to the call, TG Therapeutics will release its financial results via a press release, which is expected to detail key metrics and insights into its financial health. This initiative reflects the company’s commitment to keeping its investors and the public informed.
About TG Therapeutics
TG Therapeutics is complemented by a strong research pipeline and a commitment to treating B-cell diseases. The company's crowning achievement is the FDA approval of BRIUMVI® (ublituximab-xiiy), aimed at treating adult patients with relapsing forms of multiple sclerosis (RMS). This includes approvals in the European market by the European Commission and regulatory bodies in the UK. With such advancements, TG Therapeutics continues to pave the way in biopharmaceutical innovations crucial to patient care.
Product and Development Focus
BRIUMVI® has proved pivotal in TG Therapeutics’ portfolio and is indicative of the company’s strategic focus on developing novel therapies that address significant unmet medical needs. The progress in their clinical trials is closely monitored by investors and healthcare professionals alike, fostering a sense of optimism regarding future announcements and product launches.
Connect with TG Therapeutics
The company actively engages with its audience on social media platforms to share updates on their advancements and interact with their community. Keep an eye on their progress by checking out their updates on X (formerly Twitter) and LinkedIn, ensuring you are informed of their latest developments.
Contact Information
For investors interested in more information, TG Therapeutics can be reached for inquiries through email at ir@tgtxinc.com. You can also contact their Investor Relations team via telephone at 1.877.575.TGTX (8489), Option 4. Media inquiries can be directed to media@tgtxinc.com or by calling the same number, but selecting Option 6.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss TG Therapeutics' financial results for Q2 2025 and provide a business outlook for the remainder of the year.
How can I participate in the conference call?
To join the call, you can dial 1-877-407-8029 for U.S. callers or 1-201-689-8029 for international listeners.
Where can I find the audio replay of the call?
The audio replay will be available on TG Therapeutics' official website for 30 days after the conference call.
What is BRIUMVI® used for?
BRIUMVI® is a treatment for adult patients with relapsing forms of multiple sclerosis, which includes several disease variants.
How can investors get in touch with TG Therapeutics?
Investors can contact TG Therapeutics' Investor Relations via email at ir@tgtxinc.com or call 1.877.575.TGTX (8489), Option 4.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
